

# Alvaro Moreno-Aspitia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3504922/publications.pdf>

Version: 2024-02-01

33  
papers

1,449  
citations

430442

18  
h-index

433756

31  
g-index

35  
all docs

35  
docs citations

35  
times ranked

2738  
citing authors

#	ARTICLE	IF	CITATIONS
1	Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2022, 6, 120-125.	1.2	10
2	Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. <i>Clinical Breast Cancer</i> , 2022, 22, 308-318.	1.1	2
3	Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). <i>European Journal of Cancer</i> , 2021, 148, 287-296.	1.3	11
4	Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY). <i>Clinical Cancer Research</i> , 2021, 27, 4696-4699.	3.2	7
5	Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial. <i>ESMO Open</i> , 2020, 5, e000979.	2.0	2
6	N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 613-622.	1.1	0
7	Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. <i>Clinical Cancer Research</i> , 2019, 25, 4422-4430.	3.2	6
8	Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between <i>SLC38A7</i> and <i>ALPPL2</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 219-227.	2.3	10
9	DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. <i>Journal of Clinical Investigation</i> , 2018, 128, 2376-2388.	3.9	134
10	Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	13
11	Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	61
12	Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. <i>Breast Cancer Research</i> , 2017, 19, 130.	2.2	53
13	Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors. <i>PLoS ONE</i> , 2016, 11, e0153411.	1.1	30
14	N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. <i>Clinical Breast Cancer</i> , 2016, 16, 23-30.	1.1	42
15	Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2016, 16, 82-86.	1.1	37
16	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 2361-2369.	0.8	197
17	Folate Receptor-1 (FOLR1) Expression and Function in Triple Negative Tumors. <i>PLoS ONE</i> , 2015, 10, e0122209.	1.1	103
18	Current strategies for the prevention of breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2014, 6, 59.	1.0	30

#	ARTICLE	IF	CITATIONS
19	Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines. World Journal of Clinical Oncology, 2014, 5, 529.	0.9	47
20	Overview of nanoparticle albumin-bound paclitaxel in metastatic breast cancer. Breast Cancer Management, 2013, 2, 221-229.	0.2	0
21	RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Research and Treatment, 2013, 138, 427-435.	1.1	17
22	Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831. Cancer, 2013, 119, 2675-2682.	2.0	46
23	Neoadjuvant therapy in early-stage breast cancer. Critical Reviews in Oncology/Hematology, 2012, 82, 187-199.	2.0	21
24	Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4491-4497.	0.8	228
25	Clinical overview of sorafenib in breast cancer. Future Oncology, 2010, 6, 655-663.	1.1	26
26	Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. Journal of Clinical Oncology, 2009, 27, 11-15.	0.8	156
27	Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends. Clinical Therapeutics, 2009, 31, 1619-1640.	1.1	54
28	Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clinic Proceedings, 2009, 84, 533-45.	1.4	36
29	Thalidomide therapy in adult patients with myelodysplastic syndrome. Cancer, 2006, 107, 767-772.	2.0	38
30	North Central Cancer Treatment Group N0531: Phase II Trial of Weekly Albumin-Bound Paclitaxel (ABI-007; Abraxane®) in Combination with Gemcitabine in Patients with Metastatic Breast Cancer. Clinical Breast Cancer, 2005, 6, 361-364.	1.1	21
31	Marked Elliptocytosis in Myelodysplastic Syndromes (MDS) Is Associated to Deletion of Chromosome 20q.. Blood, 2005, 106, 4927-4927.	0.6	6
32	Platelet Count Is a Sensitive Predictor of Bone Marrow Reserve and Autologous Peripheral Blood Progenitor Cell Mobilization.. Blood, 2005, 106, 5280-5280.	0.6	0
33	Anagrelide-Associated Cardiomyopathy in Polycythemia Vera and Essential Thrombocythemia.. Blood, 2004, 104, 1515-1515.	0.6	4